• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Long term outcomes of radical radiotherapy with hypoxia modification with biomarker discovery for stratification: Ten year update of the BCON (Bladder CarbOgen Nicotinamide) phase III randomised trial (ISRCTN45938399)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Song, Yee Pei
    Mistry, Hitesh
    Irlam, Joely J
    Valentine, Helen R
    Yang, Lingjian
    Lane, Brian
    West, Catharine M L
    Choudhury, Ananya
    Hoskin, Peter J
    Affiliation
    Division of Cancer Sciences, The University of Manchester, Manchester, UK; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, U
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background: Many muscle invasive bladder cancers are hypoxic which limits efficacy of radiotherapy. Hypoxia modification using carbogen and nicotinamide has been tested in a phase III trial, XXXX. We present mature follow up with biomarker prediction of outcome. Patients and methods: XXXX is a prospective phase III multicentre randomised two arm non-blind clinical trial. Randomisation was to a control arm receiving radical radiotherapy alone or with the addition of carbogen (98% O2, 2% CO2) and nicotinamide (CON). Patients with muscle invasive or high grade non muscle invasive bladder cancer were included. Tumour tissue was collected at entry and has been analysed for tumour necrosis, hypoxia (24-gene signature) and basal and luminal tumour molecular subtypes. Overall and disease free survival and relationships with biomarker status outcome are analysed using multivariable Cox regression and log-rank analysis. Results: 333 patients with a median follow up of 10.3 years were analysed. 10-year OS rates were 30% (95% CI 0.23-0.39) in RT+CON patients and 24% (95% CI 0.18-0.33) in the RT alone patients (HR = 0.80; 95% CI: 0.61-1.04; p=0.08). Greatest benefit from CON is seen in patients with tumour necrosis (n=79; 5 yr OS 53% v 33%; HR 0.59; 95% CI 0.36-0.99; p=0.04). The results for high hypoxia gene score (n=75) were 5 yr OS 51% v 34%; HR 0.64; 95% CI 0.38-1.08; p=0.09 and molecular subtype basal (n=70) were 5 yr OS 58% vs 38%; HR 0.58; 95% CI 0.32-1.06; p=0.08. Conclusions: Although the improvement in long term overall survival in the whole population is not statistically significant, patients selected by necrosis and a high hypoxia gene score benefitted from hypoxia modification.
    Citation
    Song YP, Mistry H, Irlam J, Valentine H, Yang L, Lane B, et al. Long term outcomes of radical radiotherapy with hypoxia modification with biomarker discovery for stratification: Ten year update of the BCON (Bladder CarbOgen Nicotinamide) phase III randomised trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys. 2021.
    Journal
    International Journal of Radiation Oncology Biology Physics
    URI
    http://hdl.handle.net/10541/623959
    DOI
    10.1016/j.ijrobp.2021.03.001
    PubMed ID
    33689854
    Additional Links
    https://dx.doi.org/10.1016/j.ijrobp.2021.03.001
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ijrobp.2021.03.001
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
    • Authors: Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, Hoskin PJ, West CM
    • Issue date: 2013 Jul
    • Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
    • Authors: Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ, BCON investigators
    • Issue date: 2009 Apr
    • Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
    • Authors: Hoskin PJ, Rojas AM, Phillips H, Saunders MI
    • Issue date: 2005 Jun 1
    • Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
    • Authors: Hoskin PJ, Saunders MI, Phillips H, Cladd H, Powell ME, Goodchild K, Stratford MR, Rojas A
    • Issue date: 1997
    • Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
    • Authors: Hoskin PJ, Saunders MI, Dische S
    • Issue date: 1999 Oct 1
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.